FDA Approves Guardant’s Guardant360 CDX Comprehensive Genomic Profile

The liquid-biopsy test is also a companion diagnostic for osimertinib, AstraZeneca’s drug for non-small cell lung cancer.

test-tube-DNA
• Source: shutterstock.com

The US Food and Drug Administration approved Guardant Health, Inc.’s Guardant360 CDx comprehensive genomic profiling test for patients with any solid malignant tumor, the company announced on 7 August.

The FDA also approved it as a companion diagnostic to identify non-small cell lung cancer patients with epidermal growth factor...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Approvals

More from Policy & Regulation